Cargando…

Immune checkpoints bone marrow expression as the predictor of clinical outcome in myelodysplastic syndrome

AIMS: In our single-center retrospective study we evaluated whether level of different checkpoint molecules in bone marrow biopsies at diagnosis affect the clinical course of patients with myelodysplastic syndrome (MDS). METHODS AND RESULTS: A consecutive cohort of 55 MDS patients treated in our cen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tcvetkov, Nikolai, Gusak, Artem, Morozova, Elena, Moiseev, Ivan, Baykov, Vadim, Barabanshikova, Maria, Lepik, Kirill, Bakin, Evgenyi, Vlasova, Julia, Osipova, Anna, Zubarovskaya, Ludmila, Afanasyev, Boris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364161/ https://www.ncbi.nlm.nih.gov/pubmed/32695574 http://dx.doi.org/10.1016/j.lrr.2020.100215

Ejemplares similares

High mutation burden in the checkpoint and micro-RNA processing genes in myelodysplastic syndrome
por: Moiseev, Ivan Sergeevich, et al.
Publicado: (2021)

Landscape of alterations in the checkpoint system in myelodysplastic syndrome and implications for prognosis
por: Moiseev, Ivan, et al.
Publicado: (2022)

Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations
por: Gusak, Artem, et al.
Publicado: (2021)

P738: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELODYSPLASTIC SYNDROME: A RETROSPECTIVE COHORT MATCHED STUDY
por: Kotselyabina, Polina, et al.
Publicado: (2023)

Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML
por: Niederwieser, Christian, et al.
Publicado: (2021)

Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review
por: Morozova, E.V., et al.
Publicado: (2015)

P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila, et al.
Publicado: (2022)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma
por: Lepik, Kirill V., et al.
Publicado: (2020)

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin Lymphoma After Nivolumab Monotherapy Failure
por: Lepik, Kirill V., et al.
Publicado: (2020)

Extracorporeal Photopheresis in Children with Chronic Graft-Versus-Host Disease
por: Kozlov, Andrey, et al.
Publicado: (2021)

Efficacy and safety of nivolumab combined with brentuximab vedotin after nivolumab monotherapy failure in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila V., et al.
Publicado: (2021)

P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Fedorova, L., et al.
Publicado: (2022)

Bone marrow niches in myelodysplastic syndromes
por: Tosato, Giovanna, et al.
Publicado: (2021)

Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update
por: Jain, Akriti G., et al.
Publicado: (2022)

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
por: Kouroukli, Olga, et al.
Publicado: (2022)

MBCL-03. RESULTS OF HIGH-DOSE THIOTEPA, CARBOPLATIN AND ETOPOSIDE WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR PATIENTS WITH RECURRENT MEDULLOBLASTOMA
por: Gevorgian, Asmik, et al.
Publicado: (2020)

The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes
por: Chokr, Nora, et al.
Publicado: (2018)

The growth of myelodysplastic bone marrow in long-term cultures.
por: Borbenyi, Z., et al.
Publicado: (1987)

Hybrid inorganic-organic capsules for efficient intracellular delivery of novel siRNAs against influenza A (H1N1) virus infection
por: Timin, Alexander S., et al.
Publicado: (2017)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

Trends in Outcome of Hematopoietic Stem Cell Transplantation: 5000 Transplantations and 30 Years of Single-Center Experience
por: Zubarovskaya, Ludmila Stepanovna, et al.
Publicado: (2023)

Practical Guide to Bone Marrow Sampling for Suspected Myelodysplastic Syndromes
por: Ridgeway, Jean A., et al.
Publicado: (2017)

Myelodysplastic hematopoiesis mimicking the bone marrow in a mediastinal myelolipoma
por: Takano, Hina, et al.
Publicado: (2017)

P1179: PROGNOSIS OF PATIENTS WITH AGGRESSIVE REFRACTORY B-NHL TREATED WITH GLOFITAMAB IN REAL CLINICAL PRACTICE
por: Fedorova, Liudmila, et al.
Publicado: (2023)

Human bocavirus is not detectable in bone marrow from patients with myelodysplastic syndromes
por: Schildgen, Verena, et al.
Publicado: (2011)

Analysis of Immune-Cell Distribution of Bone Marrow in Patients with Myelodysplastic Syndrome
por: Lin, Chun-Liang, et al.
Publicado: (2023)

Synthesis of 3-(Pyridin-2-yl)quinazolin-2,4(1H,3H)-diones via Annulation of Anthranilic Esters with N-pyridyl Ureas †
por: Baykova, Svetlana O., et al.
Publicado: (2023)

Increased Expression of Interferon Signaling Genes in the Bone Marrow Microenvironment of Myelodysplastic Syndromes
por: Kim, Miyoung, et al.
Publicado: (2015)

Nature or Nurture? Role of the Bone Marrow Microenvironment in the Genesis and Maintenance of Myelodysplastic Syndromes
por: Mian, Syed A., et al.
Publicado: (2021)

Dysfunctional bone marrow endothelial progenitor cells are involved in patients with myelodysplastic syndromes
por: Xing, Tong, et al.
Publicado: (2022)

When Ring Sideroblasts on Bone Marrow Smears Are Inconsistent with the Diagnosis of Myelodysplastic Neoplasms
por: Girard, Sandrine, et al.
Publicado: (2022)

Immune checkpoints represent a promising breakthrough in targeted therapy and prognosis of myelodysplastic syndrome
por: Guo, Xinyu, et al.
Publicado: (2023)

Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis
por: Ramos, Fernando, et al.
Publicado: (2016)

Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

Deep learning application of the discrimination of bone marrow aspiration cells in patients with myelodysplastic syndromes
por: Lee, Nuri, et al.
Publicado: (2022)

The bone marrow stroma in human myelodysplastic syndrome reveals alterations that regulate disease progression
por: Kfoury, Youmna S., et al.
Publicado: (2023)

Room Temperature Synthesis of Bioactive 1,2,4-Oxadiazoles †
por: Baykov, Sergey V., et al.
Publicado: (2023)

Early Improvement in Marrow Fibrosis Following Haploidentical Stem Cell Transplantation for a Patient with Myelodysplastic Syndrome with Bone Marrow Fibrosis
por: Takahashi, Shuichiro, et al.
Publicado: (2016)

Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes
por: Yao, Kevin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8aqctirq94vei9ernqftu5cou3